KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy

被引：0
|
作者：
Danenberg, K. D.
Grimminger, P. P.
Mack, P. C.
Danenberg, P. V.
Cooc, J.
Stephens, C.
Reddy, S. K.
Li, T.
Gandara, D. R.
机构：
[1] Response Genet, Los Angeles, CA USA
[2] Univ Cologne, Dept Gen Visceral & Canc Surg, D-50931 Cologne, Germany
[3] Univ Calif Davis, Sacramento, CA 95817 USA
[4] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[5] Harbor UCLA Med Ctr, Los Alamitos, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10529
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PREDICTIVE VALUE OF KRAS AND BRAF MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH CHEMOTHERAPY
    Dingemans, Anne-Marie
    Smit, Egbert F.
    Heideman, Danielle
    Mellema, Wouter
    Derks, Jules
    Van, Robertjan Suylen
    Thunnissen, Erik
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1044 - S1044
  • [42] Predictive and prognostic value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy
    Mellema, Wouter W.
    Dingemans, Anne-Marie C.
    Smit, Egbert F.
    Derks, Jules
    Heideman, Danielle A. M.
    van Suylen, Robertjan
    Thunnissen, Frederik B.
    CLINICAL CANCER RESEARCH, 2012, 18 (03)
  • [43] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors
    Benesova, Lucie
    Minarik, Marek
    Jancarikova, Dana
    Belsanova, Barbora
    Pesek, Milos
    ANTICANCER RESEARCH, 2010, 30 (05) : 1667 - 1671
  • [44] EGFR mutations in non-small cell lung cancer - Clinical implications
    Charpidou, Andriani
    Blatza, Despoina
    Anagnostou, Elsa
    Syrigos, Konstantinos N.
    IN VIVO, 2008, 22 (04): : 529 - 536
  • [45] Cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Pirker, Robert
    LUNG CANCER, 2012, 77 : S13 - S14
  • [46] KRAS-targeted therapy in the treatment of non-small cell lung cancer
    Yun, Jina
    Nakagawa, Reid
    Tham, Kenneth
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, : 422 - 430
  • [47] Clinical characteristics, co-mutations and outcomes of advanced non-small cell lung cancer (NSCLC) patients with KRAS mutations.
    Muthiah, Arun
    Chudasama, Rani
    Olszewski, Adam J.
    Saiganesh, Harish
    Kurt, Habibe
    Mingrino, Jennifer
    Garcia-Moliner, Maria
    Azzoli, Christopher G.
    Khurshid, Humera
    Birnbaum, Ariel E.
    Khan, Hina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Mutations of EGFR and KRAS Genes in Belorussian Patients With Non-Small Cell Lung Cancer
    Mikhalenka, Alena
    Shchayuk, Anna
    Krupnova, Evelina
    Shapetska, Michael
    Chebotaryova, Natalia
    Pissarchik, Svetlana
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S509 - S510
  • [49] CLINICOPATHOLOGICAL FEATURES IN NON-SMALL CELL LUNG CANCER PATIENTS WITH EGFR AND KRAS MUTATIONS
    Nishii, Teppei
    Yokose, Tomoyuki
    Miyagi, Yohei
    Ito, Hiroyuki
    Watanabe, Masato
    Imamura, Naoko
    Isaka, Tetsuya
    Imai, Kentaro
    Karino, Fumi
    Murakami, Shuji
    Kondo, Tetsuro
    Saito, Haruhiro
    Oshita, Fumihiro
    Yamada, Kouzo
    Nakayama, Haruhiko
    Masuda, Munetaka
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S965 - S965
  • [50] Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
    Sun, Jong-Mu
    Hwang, Deok Won
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    PLOS ONE, 2013, 8 (05):
12345